AzTrials
AzTrials

Physical InactivityNCT04743856

The Clinical Referral to Activity Study

A study testing ActiveGOALSv2 and PAT in people with Physical Inactivity and Cardiovascular Risk Factor, run by University of Pittsburgh at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main aim of this effort is to test a physical activity intervention, for adult clinical care patients at risk of developing cardiovascular disease. The intervention includes social-cognitive theory-based sessions, remote coaching, a body worn physical activity tracker (PAT), and is delivered online over one year. Read more about this study

Who is it for?
Ages 40 to 70 yearsHealthy volunteers can take part
What is being tested?
ActiveGOALSv2 and PAT
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
1 siteUnited States
Study dates
29 Mar 2022to 10 Dec 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age 40-70 years of age
  • Low physical activity (PA) levels (<150 minutes/week)
  • At least one of the following common cardiometabolic risk factors:
  • high blood pressure:> 129 mm hg SP or >89 mm hg DP or medication
  • high fasting glucose:>100 mg/dl or high HbA1c: ≥42 mmols/mol or medication
  • overweight/ obesity: BMI ≥25 kg/m2).
Show all 9Show fewer
  • Have access to the internet
  • Able to read English at a 6th grade level
  • Have primary care provider (PCP) permission to increase physical activity without supervision.

Who cannot join

  • Have participated in a physical activity intervention program with behavior tracking and goal setting in the past year.
  • Told by a physician that they have diabetes (other than previous gestational diabetes) or have received a diagnosis of cardiovascular disease, regardless of when.
  • Pregnant or planning a pregnancy in <12 months
  • Non-ambulatory or planning a procedure that will lead to not being ambulatory in <12 months.
  • Women who become pregnant during the study will be required to get an updated referral form from their primary care provider (PCP) stating that they are able to increase their physical activity without supervision .

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15261

Other trials in United States

About this study

Official title: Advancement of Clinical Referral to Physical Activity for Cardiometabolic Disease Prevention

The main aim of this effort is to test a physical activity intervention, for adult clinical care patients at risk of developing cardiovascular disease. The intervention includes social-cognitive theory-based sessions, remote coaching, a body worn physical activity tracker (PAT), and is delivered online over one year. The investigators hypothesis that this intervention will be more successful at increasing physical activity (defined as objectively measured step counts and % of individuals meeting the moderate-vigorous physical activity goal) as an active control group who receives a body worn PAT and information on the CDC activity recommendations. The proposed intervention will be aligned with efforts by the US Centers for Disease Control to increase population physical activity levels and the American College of Sports Medicine (ACSM) to increase physical activity prescription in primary care.

Read the detailed description

The main aim of this effort is to test a physical activity intervention, for adult clinical care patients at risk of developing cardiovascular disease. The intervention includes 13 weekly and 6 monthly social-cognitive theory-based sessions, remote coaching, a body worn physical activity tracker (PAT), and is delivered online over one year.

A total of n=54 Clinical care patients aged 40-70 years of age with low physical activity (PA) levels (<150 minutes/week) at risk for cardiovascular disease will be recruited. Study outcomes will be measured at baseline, 6 months after intervention start and 12 months after intervention start.

For the primary outcomes, the investigators hypothesize that participants randomized to ActiveGOALSv2 + PAT will have significantly larger (a) increases in step counts/day and % meeting moderate-vigorous physical activity goal of 150 minutes/week (to 12 months) compared to the active PAT control group. Descriptive analyses and graphic displays will be used to identify outliers, missing data, and pattern of attrition. To ensure rigor, the primary analytic strategy will be a linear or generalized mixed-effect models approach in which treatment group, time, and time by group interaction are treated as fixed effects, and subject is treated as a random effect to account for individual subject variability (two sided hypothesis test; .05 level). Mixed models are applicable to longitudinal datasets that contain missing observations, (assuming data is missing at random). Regression modeling will be conducted to adjust for important covariates. The investigators will perform similar analyses to examine changes in secondary outcomes. Descriptive statistics on patient experience, beliefs/attitudes related to maintenance of physical activity changes, and program cost will also be reported.

Power and sample size: For a 2 sided test with alpha level set at .05, and assuming 20% attrition at 12 months, the investigators plan to recruit 54 participants to identify clinically relevant mean difference between randomized groups at 12-months of 2000 steps/day (with a power of .80), and 35% meeting MVPA goal (with a power of .80), given reference mean (sd) values were calculated from baseline waist worn accelerometer data from the current K12 of: 5250 (2200) steps/ day and the investigators assume 5% meeting goal at baseline in the control group.

Descriptive statistics will be used to describe the total eligible population, those referred, and those referred who participated in the study; in order to determine program reach. Exploratory Analysis of Important Pre-Existing Factors: Factor analysis will be used to identify importance of factors related to physical activity levels/ activity goal achievement over the 12 month follow-up (Mplus) from participant EHR data collected prior to intervention start. Factor structures of how individual factors contribute to activity outcomes will be explored at each time point. The best factor structure will be determined with Eigenvalues and fit indices (RMSEA, CFI, and TLI). Factor structures at the 2 time points will be compared at three levels to establish measurement invariance: 1) Configural equivalence, number of factors/ pattern of factor-indicator relationships are identical over time; 2) Metric equivalence, factor loadings are equal over time; and 3) Scalar equivalence, means and values are equivalent over time. Finally, the investigators will use descriptive statistics to report presence/absence of data on physical activity levels, cardiometabolic, and patient-centered outcomes in the EHR. The investigators will apply the same regression approaches utilized in Aim 1a to determine differences between randomized groups for EHR reported outcomes.

Being tested
ActiveGOALSv2, PAT
Keywords
Physical activity, Online lifestyle Intervention, Cardiovascular disease, Disease prevention
Medical subject headings
Sedentary Behavior, Obesity, Prediabetic State, Motor Activity, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ActiveGOALSv2Behavioural

    13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.

  • PATBehavioural

    Participants will receive a physical activity tracker and encouragement to increase activity.

Study groups in NCT04743856
Study groupRoleWhat they receive
PAT (Physical activity monitor)Active comparatorParticipants will receive a physical activity tracker and encouragement to increase physical activity.
Receives: Behavioral: PAT
ActiveGOALSv2ExperimentalParticipants will receive the ActiveGOALS online program with an integrated activity tracker.
Receives: Behavioral: ActiveGOALSv2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Meeting the Aerobic Activity Goal at 12 Months

    Change between 0 and 12 months for y/n meeting the 150 minute/week moderate-vigorous activity goal based on minutes of activity from accelerometer

    Measured: 12 months versus baseline

  2. Change From Baseline in Step Counts at 12 Months

    Objectively measured change in step counts between 0 and 12 months using ActiGraph accelerometer

    Measured: 12 months versus baseline

Secondary outcomes (15)
  1. Sedentary Behavior Minutes Over All Timepoints for 12 Months

    Objectively measured sedentary behavior at each timepoint using ActiGraph accelerometer worn for 1 week, data for a given timepoint was averaged using only valid days during that week to assess average minutes/day. Valid days are days the monitor was worn for 10 or more hours.

    Measured: baseline, 6 and 12 months

  2. Moderate-vigorous Activity Minutes Over All Timepoints for 12 Months

    Objectively measured moderate-vigorous activity at each timepoint using ActiGraph accelerometer worn for 1 week, data for a given timepoint was averaged using only valid days during that week to assess average minutes/day. Valid days are days the monitor was worn for 10 or more hours.

    Measured: baseline, 6 and 12 months

  3. Light Activity Minutes Over All Timepoints for 12 Months

    Objectively measured Light activity at each timepoint using ActiGraph accelerometer worn for 1 week, data for a given timepoint was averaged using only valid days during that week to assess average minutes/day. Valid days are days the monitor was worn for 10 or more hours.

    Measured: baseline, 6 and 12 months

  4. Step Counts Over All Timepoints for 12 Months

    Objectively measured Step counts at each timepoint using ActiGraph accelerometer worn for 1 week, data for a given timepoint was averaged using only valid days during that week to assess average steps/day. Valid days are days the monitor was worn for 10 or more hours.

    Measured: baseline, 6 and 12 months

  5. Patient Experience

    patient experience survey designed for this study with the help of patient partners to gather feedback from participants. Feedback will be used in the development of future interventions

    Measured: measured at 6 and 12 months

  6. Systolic Blood Pressure Over All Timepoints for 12 Months

    Taken by trained clinic staff using a validated automated blood pressure cuff after participant is seated in an upright position for 5 minutes. Two measure will be taken and the average of the two measures will be used. If the measures are not within 5 mmHG, a third measure will be taken.

    Measured: measured at baseline, 6 and 12 months

  7. Body Weight Over All Timepoints for 12 Months

    will be measured in clinic by trained staff using a validated scale. Participants will be asked to take shoes off and wear light clothes. Average of two measures will be used; if weight is more than .5 pounds different, a third will be taken.

    Measured: measured at baseline, 6 and 12 months

  8. Waist Circumference Over All Timepoints for 12 Months

    will be measured above the iliac crest in clinic by trained staff. Two measures will be taken and averaged; if measures are more than 1 cm different a third measure will be taken.

    Measured: measured at baseline, 6 and 12 months

  9. Fasting Blood Glucose Over All Timepoints for 12 Months

    A fasting blood draw will be taken after 12-16 hours fast.

    Measured: measured at baseline, 6 and 12 months

  10. HbA1c Over All Timepoints for 12 Months

    A fasting blood draw will be taken after 12-16 hours fast.

    Measured: measured at baseline, 6 and 12 months

  11. LDL Cholesterol Over All Timepoints for 12 Months

    A fasting blood draw will be taken after 12-16 hours fast.

    Measured: measured at baseline, 6 and 12 months

  12. HDL Cholesterol Over All Timepoints for 12 Months

    A fasting blood draw will be taken after 12-16 hours fast.

    Measured: measured at baseline, 6 and 12 months

  13. Perceived Health Score Over All Timepoints for 12 Months

    EuroQAL Visual Analogue Scale (EQ-VAS)-Self-reported perception of health on a 0 (lowest possible) to 100 (highest possible) scale.

    Measured: measured at baseline, 6 and 12 months

  14. Insulin Over All Timepoints for 12 Months

    A fasting blood draw will be taken after 12-16 hours fast.

    Measured: measured at baseline, 6 and 12 months

  15. Triglycerides Over All Timepoints for 12 Months

    A fasting blood draw will be taken after 12-16 hours fast.

    Measured: measured at baseline, 6 and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2021
  2. Study start29 Mar 2022
  3. Primary completion30 Sep 2024
  4. Study completion10 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be randomized 1:1 to one of two intervention conditions.
Masking
Double blind
Who is masked
Care provider, Outcomes assessor
Enrolment
54 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04743856
Sponsor's protocol ID
STUDY20030079
Other IDs
1K01HL151668-01
Status last verified
Apr 2026
First submitted
10 Jan 2021
Last updated
12 May 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing ActiveGOALSv2 and PAT in people with Physical Inactivity and Cardiovascular Risk Factor, run by University of Pittsburgh at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Nov 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Meeting the Aerobic Activity Goal at 12 Months (time frame: 12 months versus baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in